The research team engineered CD8+ Jurkat T cells to express SVAR16, a human TCR with intermediate-to-high 2D affinity for the SARS-CoV-2-derived epitope HLAA2:01–YLQ, using lentiviral transduction.
Modified, autologous T-cell immunotherapies have been transformative in the treatment of hematologic malignancies with several approvals of chimeric antigen receptor T-cell therapies to treat lymphoma ...
Phase I trial of personalized AI-identified TCR-transduced T cell therapy in advanced solid tumors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results